REGN

ABBV AMGN AMGN:CA BAYRY BAYZF Biotechnology BMY GILD IPSEF IPSEY JNJ JNJ:CA LLY LLY:CA NONOF NOVO:CA NVO NVON:CA NVS NVS:CA NVSEF PFE PFE:CA REGN RHHBF RHHBY RHHVF Robert J. Lake ROCH:CA ROG:CA SAN:CA SNY SNY:CA SNYNF Uncategorized VRTX ZLLY:CA ZPFE:CA

Regeneron: Fairly Valued Now After A Stellar Upswing

Mar 11, 2026

Biotechnology NTLA REGN Uncategorized

Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM

Mar 2, 2026

Biotechnology REGN SNY Uncategorized

EMA panel recommends Dupixent indication for urticaria in children

Feb 27, 2026

ALLKA Research AMGN BIIB Biotechnology REGN RHHBY Uncategorized

Why Dupixent Keeps Regeneron A Top Big Pharma Pick

Feb 27, 2026

AZN BBIO BIIB Biotechnology Bret Jensen GSK IONS NTLA NVS PFE REGN Uncategorized

Ionis Pharmaceuticals: Digesting Recent Events

Feb 27, 2026

Biotechnology REGN Uncategorized

Regeneron granted FDA priority review for rare bone disorder therapy

Feb 19, 2026

BAYRY BAYZF Biotechnology GCVRZ REGN SAN:CA SNY SNYNF Uncategorized

Regeneron posts Q4 beat as Sanofi collaboration offsets Eylea headwinds

Jan 30, 2026

A Biotechnology REGN Uncategorized

Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY26 outlook

Jan 30, 2026

regeneron-pharmaceuticals-q4-2025-earnings-preview

Biotechnology REGN Uncategorized

Regeneron Pharmaceuticals Q4 2025 Earnings Preview

Jan 29, 2026

Earnings News Comments Regeneron Pharmaceuticals (REGN) is scheduled to announce Q4 earnings results on Friday,...

alvotech-resolves-global-patent-disputes-with-regeneron-and-bayer-over-eylea-biosimilar

ALVO BAYZF Biotechnology REGN Uncategorized

Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar

Jan 29, 2026

Comments STAP Alvotech (ALVO) has reached a licensing and settlement agreement with Regeneron (REGN) and...

Next Page »